Kairos Pharma, Ltd. · AMEX:KAPA
Kairos Pharma — Investor Presentation (October 2024)
25 slides from Kairos Pharma's investor presentation, Oct 10, 2024
Slide 1: Investor Presentation
KAIROS if ~ PHARMA INVESTOR PRESENTATION NYSE American: KAPA kairospharma.com
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS KAIROS PHARMA This presentation may contain “forward-looking statements” regarding the current expectations and projections about future events of Kairos Pharma, Ltd. (Kairos Pharma” or the “Company"). “Forward-looking statements” (statements as to matters other than histo
Slide 3: Our Mission
OUR MISSION Kus Kairos Pharma is dedicated to advancing therapies to overcome critical challenges in cancer drug resistance and immune suppression.
Slide 4: Highlights
PHARMA HIGHLIGHTS KK sae + Three clinical programs already in progress ~ LEAD DRUG ENV105 in Phase 2 trial treating Prostate Cancer - with NIH grant funding - ENV105 Phase 1 trial treating Non-Small Cell Lung Cancer -with non-dilutive, donor funding - KROS201 cleared IND for Glioblastoma + Strategic
Slide 5: Portfolio of Innovative Drugs
PORTFOLIO OF INNOVATIVE DRUGS DRUG MODALITY/ N \ PHASE 1 \ PHASE 2 IN SS biusdiaasblaanad A A A A ENV-105 KROS-401 ENV-205 Antibody targeting CD105 to reverse resistance to anti- androgen drugs (enzalutamide, abiraterone, apalutamide) Antibody targeting CD105 to reverse resistance to EGFR targeted d
Slide 6: ENV105: Overcoming Cancer Drug Resistance
ENV105 KAI OVERCOMING CANCER DRUG RESISTANCE BHANMA Prostate Cancer 4 Lung Cancer 6a Anti-androgen drugs EGFR drugs (enzalutamide, (osimertinib, abiraterone, apalutamide) erlotinib, gefitinib) development of resistance (CD105) TGFR irs BMP4 "TORI = a ALK1 voctea 1 de-differentiation THE PROBLEM: Can
Slide 7: ENV105 in Prostate Cancer
ENV105 IN PROSTATE CANCER BHANMA ENV105 reverses resistance to enzalutamide. Enzalutamide Enzalutamide+ ENV105 ENV105 allows anti-androgen standard of care drug enzalutamide to work again to kill prostate cancer cells Left figure with growing cancer cells with enzalutamide alone after resistance dev
Slide 8: ENV105 in Prostate Cancer: Previous Phase Trial Results
ENV105 kainos IN PROSTATE CANCER PHARMA PREVIOUS PHASE 2 TRIAL RESULTS: 62% CLINICAL BENEFIT RATE Previous phase 2 trial tested whether ENV 105 could make prostate anti-androgen drugs work again when the cancer became resistant to abiraterone or enzalutamide Abiraterone + ENV105 resistant to Enzalut
Slide 9: Biomarker to Predict Responsiveness to Therapy
ENV105 cainos IN PROSTATE CANCER PHARMA BIOMARKER TO PREDICT RESPONSIVENESS TO THERAPY * Biomarker is a genetic test that distinguishes between responsive and non-responsive patients + Identified biomarkers ensure more successful outcomes in new drug approval (NDA) success + $3.2 Million NIH grant t
Slide 10: Present Randomized Phase 2 Trial
ENV105 KAIROS | IN PROSTATE CANCER PRESENT RANDOMIZED PHASE 2 TRIAL Apalutamide with or without ENV105 @-@ apalutamide single agent Recurrence on anti-androgen @-@ apalutamide + ENV105 Resistancetoanti- 4'u9 Prostate androgen drugs Cancer lupron @.... 2 mos. : sees eee eee > \ enzalutamide @.... F =
Slide 11: ENV105 in Lung Cancer
ENV105 kanos IN LUNG CANCER PHARMA NON-SMALL CELL LUNG CANCER BECOMES RESISTANT TO OSIMERTINIB (TAGRISSO) EGFR-driver (Exon19del + L858R) EGFR-dependent OSIMERTINIB RESISTANCE IS DEPENDENT ON CD105 (c7978) PET dspender’ * Tagrisso treats EGFR driven NSCLC (MET amplification) Other Pathways * 45,000
Slide 12: Phase Trial for EGFR-Driven Lung Cancer
ENV105 KAIROS PHARMA IN LUNG CANCER PHASE 1 TRIAL FOR EGFR-DRIVEN LUNG CANCER: Osimertinib (Tagrisso) + ENV105 Patients that have become . . Lung resistant to Tagrisso Cancer N = 9-20 : Patients that are incompletely Ald Safety lead-in treated with Tagrisso with C) Bayesian design N=20 persistent ct
Slide 13: Overcoming Immune Suppression
K si OVERCOMING IMMUNE SUPPRESSION Immunotherapy is a $115b market with only a 17% response rate. Cancer is comprised of billions of growing cells. However, our immune system seldom generates enough T cells to kill all the cancer cells. Generate more T cells that are more effective at killing cancer
Slide 14: KROS101 Expands T Cells; KROS102 Decreases T Cells
KROS101 expands T cells for cancer KAIROS, KROS102 decreases T cells for autoimmune diseases * KROS101 targets the GITR ligand and enables T cells to increase in numbers and kill cancer cells more effectively. * By increasing T cell numbers and function KROS101 may complement checkpoint inhibitors l
Slide 15: KROS101 GITR Agonist
PHARMA 101 GITRAGONIST Ff immunity kK set KROS 101: GITR (glucocorticoid-induced tumor necrosis factor receptor) ligand is a powerful checkpoint that increases the T cell response against cancer. KROS-101 pictured here in the center of the GITR protein Kairos Pharma developed a small molecule that i
Slide 16: KROS102 GITR Antagonist
KROS102 GITR ANTAGONIST J Immunity KA IROS PHARMA * KROS102: GITR antagonist that decreases T cell numbers and activity. KROS-102 pictured here in the * KROS-102 has been shown to decrease T effector cells (killer center of the GITR protein T cells) and increase Treg cells (inhibitory T cells) which
Slide 17: Why Kairos?
WHY KAIROS? KAIROS PHARMA Addressing oncologic failures due to cancer drug resistance and immune suppression UNMET MEDICAL NEED | DRUG | HOW KAIROS ADDRESSES UNMET MEDICAL NEED a Devel of resistance to many, otherwi: effective, cancer drugs (hormone based therapies, EGFR-based therapies, radiation,
Slide 18: Cancer Drug Resistance Is an Unmet Medical Need
° ° ° KAIROS Cancer Drug Resistance is an unmet medical need PHARMA ENV105 MARKET OPPORTUNITY BY DISEASE - 2024 ENV105 MARKET OPPORTUNITY BY DISEASE + Anti-androgen therapy prostate cancer market of $11.3 billion’. Cancer Market Chemotherapy + EGFR based lung cancer therapy market of $14 billion? An
Slide 19: Immuno-Oncology Market
KAIROS Immuno-Oncology Market PHARMA Global immunotherapy market estimates show significant compounded growth with sales expectations ranging from USD 94.7 - 126.9 Billion by 2026, exhibiting a CAGR of up to 20.2% from 2020.2 MARKET DRIVERS + Increasing patient pool and higher mortality rate are aug
Slide 20: Milestones
MILESTONES °?%@ Taos 202 t 129% t PPP oes: June 2013 - Spun-off from Cedars-Sinai Medical Center July 2016 -Name changed to Kairos Pharma and licensed immunotherapy technology from Cedars-Sinai Medical Center November 2019 - Merged with AcTcell Biopharma duly 2021- Merged with Enviro Therapeutics No
Slide 21: Strong Intellectual Property Foundation
STRONG INTELLECTUAL PROPERTY FOUNDATION KAIROS, IP extends to 2040 & Key IP generated from Murali, Published patents Exclusive, worldwide rights to IP Bhowmick and Yu labs executed internationally licensed from Cedars Sinai Medical Center KROS101 KROS201 KROS301 KROS401 ENV105, PCT/US2019/045478 PCT
Slide 22: Leading Team
LEADING TEAM John S. Yu, MD CEO & CHAIRMAN BAS from Stanford, MD from Harvard Medical School and MIT Professor of Neurosurgery, Director Surgical Neuro-Oncology at Cedars-Sinai Medical Center N i and ies from his NIH funded laboratory Developed 8 new investigational drugs with the FDA and has led nu
Slide 23: Independent Directors
INDEPENDENT DIRECTORS Rosemary Mazanet MD, Ph.D Internal Medicine and Oncology at the Brigham and Women’s Hospital/ Harvard Dana Farber Cancer Institute + 30+ year career as a celebrated Biotech investor, advisor, capital markets and C-suite executive at several biopharma companies including former
Slide 24: Summary
SUMMARY Clinical stage company with an antibody that impacts a central mechanism of cancer drug resistance Enrolling in phase 1 and 2 trials with interim efficacy data in 2025 Strategic relationship with Cedars-Sinai Medical Center (ranked #2 in the nation) provides access to medical expertise, driv
Slide 25: Investor Relations
KAIROS PHARMA 0d INVESTOR RELATIONS Louie Toma MANAGING DIRECTOR CorelR louie@coreir.com NYSE American: KAPA kairospharma.com